Гастроэнтерология / 02. ХГ. ГЭРБ / ГЭРБ / ГЭРБ (рекомендации РГА)

and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment Pharmacol Ther 2010; 31(9):1001-11.

154.Lee R.D., Vakily M., Mulford D. et al. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor — evidence for dosing flexibility. Aliment Pharmacol Ther 2009; 29(8):824-33.

155.Sarosiek I. et al. Significant Increase of Esophageal Mucin Secretion in Patients with Reflux Esophagitis After Healing with Rabeprazole: Its Esophagoprotective Potential. Dig Dis Sci 2009; 54(10):2137-42.

156.Takiuchi H., Asado S., Umegaki E., Tahashi Y.,

Ohshiba S. Effects of proton pump inhibitors:

omeprazole, lansoprazole and E 3810 on the gastric mucin. In: Proc. 10th World Congress of Gastroenterol. Los Angeles, CA; 1994. 1404 p.

157.Pandolfino J.E., Vela M.F. Esophageal-reflux moni­ toring. Gastrointest Endosc 2013; 15(4):316.

158.Galmiche J.P., Hatlebakk J., Attwood S. et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: The LOTUS randomized clinical trial. JAMA 2011; 305(19):1969-77.

159.Wileman S.M., McCann S., Grant A.M. Medical versus surgical management for GERD in adults. Cochrane Database Syst Rev 2010, pp. CD003243.

160.Rouphael C., Gordon I.O., Thota P.N. Lymphocytic esophagitis: Still an enigma a decade later. World J Gastroenterol 2017; 23(6):949-56.